Current Studies
Use the links to the right to view more information about clinical studies by year

Psoriasis
Sponsor: Amgen
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
February 2010 to Present

Acne
Sponsor: Stiefel, a GSK company
A Phase III, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris
October 2009 to Present

Acne
Sponsor: Cipher Pharmaceuticals
A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
October 2009 to Present

Obesity
Sponsor: Eli Lilly and Company
A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women
October 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operations
A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on the Head (Face or Scalp) Who Have Completed Day 57 in Studies PEP005-016 or PEP005-025
August 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operations
A Phase III Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of XXXX in Patients with Actinic Keratoses on Non-head Locations
July 2009 to Present

Herpes Zoster
Sponsor: Inhibitex
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients With Herpes Zoster
June 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operations
A Phase III Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of XXXX In Patients With Actinic Keratoses ON the Head (Face or Scalp)
June 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operatons
A Phase III Multi-center, Open-label Study to Evaluate the Safety and Efficacy of XXXX in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities)
June 2009 to Present

Psoriasis
Sponsor: Celgene Corporation
A Phase IIb, Multicenter, Treatment-Arm Blind, Safety And Efficacy 32-Week Extension Study Of XXXX In Subjects Who Completed The Treatment Phase Of The Core Study CC-10004-PSOR-005
April 2009 to Present

Chronic Obstructive Pulmonary Disease
Sponsor: Novartis
A IIIb randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 µg once daily with open label tiotropium 18 µg once daily vs open label tiotropium 18 µg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease
February 2009 to Present

Coronary Artery Disease
Sponsor: GlaxoSmithKline
A Phase III Randomized, Double Blind, Parallel Assignment, Clinical Outcomes Study of XXX Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events
February 2009 to Present

Psoriasis
Sponsor: Eli Lilly and Company
A Phase I, XXXXX (Anti-IL-17 Humanized Antibody) Multiple-Dose Safety and Tolerability Study in Subjects with Psoriasis Vulgaris
January 2009 to Present

Psoriasis
Sponsor: Abbott Laboratories
A 10-Year, Post-Marketing, Observational, Registry of XXXXX in Adult Patients with Chronic Plaque Psoriasis
November 2008 to Present

Hypertension/Diabetes Mellitus
Sponsor: Novartis
An 8-Week Randomized, Double-blind, Parallel-Group, Multicenter, Active-Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of XXXXX Compared to XXXXX in Patients with Stage 2 Systolic Hypertension and Diabetes Mellitus
November 2008 to Present

Psoriasis
Sponsor: Novo Nordisk
A Randomized, Double-blind, Placebo-Controlled, Single and Multiple dose, Dose-Escalation Trial of XXXXX in Psoriatic Subjects, Followed by an Expansion Phase.
October 2008 to Present

Psoriasis
Sponsor: Centocor, Inc.
A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
May 2008 to Present

Psoriasis
Sponsor: Abbott Laboratories
A Phase III Multicenter, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With XXXXX (M016)
March 2008 to Present

Psoriasis
Sponsor: Abbott Laboratories
Open-label Study XXXXX in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy.
November 2007 to Present

Psoriasis
Sponsor: Wyeth
A Phase I, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharamcodynamics and Clinical Efficacy of XXXXX Administered Subcutaneously or Intravenously to Subjects with Psoriasis
October 2007 to Present

Arthritis with Cardiovascular Disease
Sponsor: Pfizer
A Phase IV, Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patient With or at High Risk for Cardiovascular Disease Comparing XXXXX with Naproxen and Ibuprofen.
December 2006 to Present

Psoriasis
Sponsor: Amgen, Inc.
Observational Post-Marketing Safety Surveillance Registry of XXXXX for the Treatment of Psoriasis.
July 2006 to Present

Psoriasis
Sponsor: Centocor, Inc.
A Phase III Trial Evaluating the Efficacy and Safety of XXXXX in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis. (T09)
January 2006 to Present

Psoriasis
Sponsor: Centocor, Inc.
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of XXXXX in the treatment of Subjects With Moderate to Severe Plaque-type Psoriasis. (T08)
January 2006 to Present

Psoriasis
Sponsor: Genentech, Inc.
XXXXX Epidemiologic Study of Psoriasis Outcomes and Safety Events (RESPONSE) in Patients with Chronic Moderate to Severe Plaque Psoriasis. 
April 2004 to Present